Francois Haddad

Francois Haddad, MD, Associate Clinical Professor, Department of Medicine, Division of Cardiovascular Medicine; Director, Biomarker and Phenotypic Core Laboratory, Stanford Cardiovascular Institute, Stanford University School of Medicine

 

Research Description: Dr. Haddad’s area of expertise is heart failure and cardiovascular imaging. He directs the Stanford Cardiovascular Institute Biomarker and Phenotypic Core Laboratory. His laboratory is developing and validating criteria for the early detection of cardiovascular disease and developing comprehensive risk scores for patients with heart failure and pulmonary hypertension. His laboratory has a long history of collaboration with the Human Immune Monitoring Center, and SDRC members in the Department Genetics, the Pulmonary Division in the Dept. of Medicine and the Stem Cell Institute. As part of the Stanford DRC, Dr. Haddad’s team will provide comprehensive cardiovascular, endothelial function and exercise physiology phenotypes of study participants. They have developed methods to characterize ventricular dysfunction in patients with insulin resistance or diabetes mellitus. Their efforts with SDRC investigators will help elucidate mechanisms underlying early stages of ventricular dysfunction, endothelial dysfunction or vascular aging in patients with insulin resistance or diabetes mellitus. His contributions to our center will be essential for efforts focusing on diabetic cardiomyopathy, early vascular aging in patients with diabetes mellitus, autonomic dysfunction and drug response studies.

Selected relevant publications (Stanford DRC Members in BOLD):

1.         Kuznetsova T, Cauwenberghs N, Knez J, Yang WY, Herbots L, D'hooge J, Haddad F, Thijs L, Voigt JU, Staessen JA. Additive Prognostic Value of Left Ventricular Systolic Dysfunction in a Population-Based Cohort. Circ Cardiovasc Imaging. 2016 Jul;9(7).

2.         Vrtovec B, Sever M, Jensterle M, Poglajen G, Janez A, Kravos N, Zemljic G, Cukjati M, Cernelc P, Haddad F, Wu JC, Jorde UP. Efficacy of CD34+ Stem Cell Therapy in Nonischemic Dilated Cardiomyopathy Is Absent in Patients With Diabetes but Preserved in Patients With Insulin Resistance. Stem Cells Transl Med. 2016 May;5(5):632-8.

3.         Haddad F, Onno S, Denault AY, Mercier O, Bruner N, Furman D, Fadel E, Bogaard H, Schnittger I, Vrtovec B, Wu J, de Jesus Perez V, Vonk-Noordegraaf A, Zamanian RT- A Simple Right Heart Score for Predicting Outcome in Patients with Idiopathic, Familial or Drug and Toxin associated Pulmonary Arterial Hypertension- JACC-Cardiovascular Imaging 2015.

4.         Vrtovec B, Fister M, Poglajen G, Starc V, Haddad F. Diabetes does not affect ventricular repolarization and sudden cardiac death risk in patients with dilated cardiomyopathy. Pacing Clin Electrophysiol. 2009 Mar;32 Suppl 1:S146-50.